New drug could ease stubborn shoulder pain
NCT ID NCT05569174
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether secukinumab, an anti-inflammatory drug, can reduce pain and improve function in adults with moderate to severe rotator cuff tendinopathy (shoulder tendon pain) that didn't get better with standard treatments. 62 participants received either the drug or a placebo for 12 weeks. The main goal was to see if shoulder-related quality of life improved after 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Secukinumab (a drug that targets inflammation)
What this could lead to
If it works, this could provide a new treatment option for people with stubborn shoulder tendon pain that hasn't improved with standard care.
What could go wrong
This is a small, early-phase trial with only 62 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TENDINOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Karlsruhe, Baden-Wurttemberg, 76133, Germany
-
Novartis Investigative Site
Munich, Bavaria, 80809, Germany
-
Novartis Investigative Site
Hanover, Lower Saxony, 30159, Germany
-
Novartis Investigative Site
Halle, Saxony-Anhalt, 06120, Germany
-
Novartis Investigative Site
Bad Doberan, 18209, Germany
-
Novartis Investigative Site
Berlin, 10787, Germany
-
Novartis Investigative Site
Berlin, 12627, Germany
-
Novartis Investigative Site
Cottbus, 03042, Germany
-
Novartis Investigative Site
Dresden, 01069, Germany
-
Novartis Investigative Site
Erlangen, 91054, Germany
-
Novartis Investigative Site
Frankfurt am Main, 60313, Germany
-
Novartis Investigative Site
Gladbeck, 45968, Germany
-
Novartis Investigative Site
Hamburg, 20095, Germany
-
Novartis Investigative Site
Hamburg, 20149, Germany
-
Novartis Investigative Site
Hamburg, 22415, Germany
-
Novartis Investigative Site
Heinsberg, 52525, Germany
-
Novartis Investigative Site
Herne, 44649, Germany
-
Novartis Investigative Site
Mainz, 55131, Germany
-
Novartis Investigative Site
Schönebeck, 39218, Germany